ReviewCureus2025
The Interplay Between Varicella-Zoster Virus and Giant Cell Arteritis: An In-Depth Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reversible temporal artery halo sign in polymerase chain reaction-confirmed herpes zoster ophthalmicus without corticosteroid exposure.Rheumatology advances in practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) is a large-vessel vasculitis that is commonly associated with inflammation of the blood vessels within the head and neck. The condition primarily affects older and immunocompromised individuals and is diagnosed through a combination of physical examination, laboratory tests, and, in some cases, biopsy. Most patients present with headaches, visual disturbances, and jaw claudication accompanied by low-grade fever, fatigue, and weight loss. Varicella-zoster virus (VZV) may play a role in the pathogenesis of GCA. VZV DNA has been identified within the cerebral arteries of a patient with fatal vasculitis of the central nervous system (CNS) without dermatologic presentation. Specifically, they identified VZV DNA within the cerebral arteries of a patient with fatal vasculitis of the CNS without dermatologic presentation, which has been further explored in more recent studies. While the presence of VZV within vascular endothelial cells and within temporal artery biopsies of patients with and without GCA suggests a possible overlap with GCA, debatable findings across recent studies, combined with inconsistent replication of biopsy techniques, have raised questions. The treatment of GCA involves high-dose corticosteroids, but in some cases, antivirals have been used when patients are resistant to corticosteroid treatment or if there is a strong clinical suspicion of VZV involvement. Multiple case reports have demonstrated the effectiveness of antivirals in treating GCA, but their validation remains limited by a lack of randomized controlled trials. In this narrative literature review, we explored current research efforts exploring the relationship between VZV and GCA. This study underscores the need for additional research to gain insight into the role of VZV in the pathophysiology of GCA and to establish evidence-based, more targeted treatment approaches that improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.